Join Growin Stock Community!

Veeva systems inc(VEEV.US AI Earnings Summary)

US StockHealthcare
No presentation for VEEV

VEEV AI Earnings Summary (In-Depth)

Last updated: 2026-08-26 (US time)

2027 Q2 (Fiscal Year)

Core Highlights

Total revenue and profitability for this quarter exceeded the upper bound of guidance. All 12 objective commitments across major products were fully met, establishing a high level of execution credibility.

  • Stock Price Reaction: Prior to the earnings release (Pre-market and during trading on 8/26 EST), Veeva Systems' shares edged down 0.76% to close at $244.91. On August 27 (the first trading day after the report), the stock opened at $275.355, reached a high of $296.24 and a low of $274.81, and closed at $282.13, up 15.20% from the August 26 close of $244.91. The after-hours prints of $268.00 (+9.43%) or $266.30 (+8.73%) were not the official close.
  • Against Market Expectations: Revenue of $928M was about 2.5% above the TradingView pre-earnings market expectation of $905.38M; the TradingView pre-earnings EPS expectation was $2.22; this quarter's summary does not state a comparable actual EPS, so no EPS comparison is made.
  • Against Own Previous Guidance: All financial metrics met targets this quarter. Total revenue of $928M exceeded the high end of previous guidance ($885M); subscription revenue reached $766.8M, higher than the $730M guidance; Non-GAAP operating margin was 44.8% ($415.9M), remaining at the upper end of guidance.
  • In One Sentence: Vault CRM successfully signed major pharmaceutical companies such as Eli Lilly and Biogen while accelerating the rollout of the Veeva Falcon intelligent agent platform, with the market responding with a close of $282.13 on August 27, up 15.20%.

Quarterly Highlights

Veeva Systems Inc. (VEEV) total revenue grew 18% year-over-year this quarter, setting multiple historical records, with overall execution exceeding own expectations.

  1. Record Highs in Total Revenue and Profitability: Total revenue for the quarter (fiscal year) reached $928M, an 18% year-over-year increase, up from $883M in Q1'27; Non-GAAP operating income was $415.9M, with Non-GAAP operating margin maintained at 44.8%, nearly flat compared to 44.7% in the same period last year, demonstrating high profitability discipline while actively investing in AI. CEO Peter Gassner stated at the opening, "Q2 was another strong quarter with results ahead of our expectations."

  2. Commercial Solutions Subscription Records Best CRM Quarter Ever: Commercial solutions subscription revenue reached $347.4M, up approximately 13% year-over-year. CFO Brian Van Wagener noted that even excluding the Crossix contribution, the remaining commercial business maintained double-digit growth across multiple product lines including CRM, content management, data, Crossix, and Ostro, representing a broad-based rather than single-point driven strong performance. Management called this the "best CRM quarter ever."

  3. Steady Growth in R&D and Quality Solutions Subscriptions: R&D and Quality solutions subscription revenue reached $419.4M, up approximately 7% sequentially from $392.3M in Q1'27. The CFO noted that growth momentum is gradually shifting from mature products like eTMF and CTMS to next-generation products such as Veeva EDC, Veeva eCOA, Veeva RTSM, Safety, and Veeva LIMS, all of which are in the early stages of their respective growth curves, laying the foundation for 2030 long-term goals.

  4. Vault CRM Gains Two More Top Pharma Wins: The company successfully secured Vault CRM commitments from Eli Lilly (Ticker: LLY) and Biogen (Ticker: BIIB), two top 20 pharmaceutical companies. Along with Regeneron (Ticker: REGN), Veeva has now captured 12 of the top 20 pharmaceutical companies; only 2 remain undecided, and management expressed confidence in both. EVP Strategy Paul Shawah pointed out that over 180 customers are now live on Vault CRM, and one top 20 pharmaceutical company completed a full rep rollout of AI capabilities this quarter, marking a significant milestone.

  5. Veeva Falcon Enters Early Adopter Phase with High Demand: Falcon currently has 5 early adopter customers, including one top 20 pharmaceutical company, with the first go-lives expected within this fiscal year. CEO Peter Gassner stated: "Market interest in Falcon is very high because rapid cost savings, compliance, and efficiency gains are priorities for everyone. We are the ones limiting the speed right now—we have to get the product ready." Falcon's first targeted use cases are clinical trial document processing and drug safety (adverse event) classification, adopting a usage-based billing model per document or per case.

  6. Normalized Billings Up 19% Year-over-Year: Normalized billings for the quarter reached $768M, a 19% increase from $666M in the same period last year, indicating continued strong contract momentum and providing visibility for future subscription revenue. The full-year normalized billings expectation was raised to approximately $3.87B.

  7. Data Cloud Adds 14 Customers, Ecosystem Synergy Deepens: 14 new Data Cloud customers were added this quarter, with progress in Veeva OpenData (clean reference data), Veeva Compass (complex therapy market data), and Veeva Link (key opinion leader data). The CEO emphasized that Data Cloud is not a prerequisite for AI but an accelerator—the cleaner the data, the better the AI workflow effects, with the three (software, data, AI agents) forming a mutually reinforcing industry cloud ecosystem.

  8. First Anniversary of IQVIA Partnership Receives High Praise: CEO Peter Gassner stated his feeling toward the IQVIA (Ticker: IQV) partnership is "500% better than it was two years ago," calling it one of the most important developments for the company in the past 12 months. The collaboration has begun to bring substantial benefits to mutual customers, reducing friction between using Veeva software and IQVIA data services, and management expects more collaborative results in the future.

Sign up for free!

You can sign up for free or Log In to read more information!

Free In-Depth for popular US stocks:

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer